REZOLUTE, INC. Dilutive Share Adjustment
REZOLUTE, INC. (RZLT) reported Dilutive Share Adjustment of 50.81 million shares for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment · last filed 2024-05-15
- REZOLUTE, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2024-03-31 was 50.81M shares, a 1.16% decline year-over-year.
- REZOLUTE, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2023-12-31 was 51.41M shares, a 0.00% decline year-over-year.
- REZOLUTE, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2023-09-30 was 51.41M shares, a 1.74% increase year-over-year.
- REZOLUTE, INC. weighted average number diluted shares outstanding adjustment for the quarter ending 2023-03-31 was 51.41M shares, a 198.58% increase year-over-year.
| Period end | Weighted Average Number Diluted Shares Outstanding Adjustment 3 month | Weighted Average Number Diluted Shares Outstanding Adjustment 3 month as first filed | Weighted Average Number Diluted Shares Outstanding Adjustment 6 month | Weighted Average Number Diluted Shares Outstanding Adjustment 6 month as first filed | Weighted Average Number Diluted Shares Outstanding Adjustment 9 month |
|---|---|---|---|---|---|
| 2024-03-31 | 50.81M shares 10-Q · filed 2024-05-15 | 51.11M shares derived: average of 2 quarters · filed 2024-05-15 | 51.21M shares 10-Q · filed 2024-05-15 | ||
| 2023-12-31 | 51.41M shares 10-Q · filed 2024-02-13 | 51.41M shares 10-Q · filed 2024-02-13 | |||
| 2023-09-30 | 51.41M shares 10-Q · filed 2023-11-13 | ||||
| 2023-03-31 | 51.41M shares 10-Q · filed 2024-05-15 | 51.41M shares derived: average of 2 quarters · filed 2024-05-15 | 51.11M shares 10-Q · filed 2024-05-15 | ||
| 2022-12-31 | 51.41M shares 10-Q · filed 2024-02-13 | 50.97M shares 10-Q · filed 2024-02-13 | |||
| 2022-09-30 | 50.53M shares 10-Q · filed 2023-11-13 | ||||
| 2022-03-31 | 17.22M shares 10-Q · filed 2023-05-11 | 16.45M shares derived: average of 2 quarters · filed 2023-05-11 | 13.75M shares 10-Q · filed 2023-05-11 | ||
| 2021-12-31 | 15.68M shares 10-Q · filed 2023-02-10 | 15.68K shares 10-Q · filed 2022-02-09 | 12.10M shares 10-Q · filed 2023-02-10 | 12.10K shares 10-Q · filed 2022-02-09 | |
| 2021-09-30 | 7.45M shares 10-Q · filed 2022-11-09 | ||||
| 2021-03-31 | 8.35M shares 10-Q · filed 2022-05-12 | 4.18M shares derived: average of 2 quarters · filed 2022-05-12 | 7.45M shares 10-Q · filed 2022-05-12 | ||
| 2020-12-31 | 8.04K shares 10-Q · filed 2022-02-09 | 6.96K shares 10-Q · filed 2022-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |